LipoScience, Inc. announced data on their nuclear magnetic resonance (NMR)-based diagnostic test to identify normal-weight individuals at high risk of developing type 2 diabetes. Data on this diabetes risk index (DRI) was presented at the 2014 American Diabetes Association Scientific Sessions.
NMR data from participants in the Multi-Ethnic Study of Atherosclerosis (MESA) was collected at baseline in the development of the DRI assay, which utilizes proprietary NMR-derived markers of insulin resistance, inflammation, and potentially impaired B-cell function to assess the patient’s risk of type 2 diabetes. Data from the Insulin Resistance Atherosclerosis Study (IRAS) was used to confirm the DRI score’s ability to identify normal-weight individuals with a high likelihood of developing type 2 diabetes.
The DRI score increased as there was in increased likelihood of developing type 2 diabetes, regardless of BMI category and added predictive value independently in both the IRAS and MESA populations.
For more information visit LipoScience.com.